AbbVie's Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
Elahere achieved a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase II trial.
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase II trial.
A high ORR in a single‑arm Phase II study suggests that Elahere, an antibody–drug conjugate targeting folate receptor alpha, offers a promising new therapeutic option for patients with platinum‑sensitive ovarian cancer—a population that remains challenging to treat and with limited new approvals.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements